Affiliation: GlaxoSmithKline Research and Development
- The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory markerAndrew Lockhart
GlaxoSmithKline, Translational Medicine and Technology, Addenbrooke s Centre for Clinical Investigation, Addenbrooke s Hospital, Cambridge CB2 2GG, UK
Nucl Med Biol 30:199-206. 2003..Finally, local synthesis of AGP at the site of brain injury may contribute the pattern of [(11)C]PK11195 binding observed in neuroinflammatory diseases...
- In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brainLiang Ye
GlaxoSmithKline, Clinical Science and Technology, Neurology DM, New Frontiers Science Park, Harlow, UK
J Neurochem 105:1428-37. 2008..Lewy bodies pathology is therefore unlikely to contribute significantly to the retention of PIB in positron emission tomography imaging studies...
- Imaging Alzheimer's disease pathology: one target, many ligandsAndrew Lockhart
GlaxoSmithKline, Addenbrooke s Centre for Clinical Investigation ACCI, Box No 128, Addenbrookes Hospital, Hills Road, Cambridge CB2 2GG, UK
Drug Discov Today 11:1093-9. 2006....
- PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosisA Lockhart
GlaxoSmithKline, Clinical Science and Technology, CPDM and NGI CEDD, NFSP North, Third Avenue, Harlow, Essex, CM19 5AW, UK
Brain 130:2607-15. 2007....
- Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrilsAndrew Lockhart
Translational Medicine and Technology, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge CB2 2GG, United Kingdom
J Biol Chem 280:7677-84. 2005..The presence of additional ligand-binding sites presents potential new targets for ligand development and may allow a more complete modeling of the current positron emission tomography data...
- Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrilsLiang Ye
Translational Medicine and Genetics, GlaxoSmithKline Research and Development, Addenbrookes Hospital, Cambridge, CB2 2GG, United Kingdom
J Biol Chem 280:23599-604. 2005....
- Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymersLiang Ye
GlaxoSmithKline Research and Development, Translational Medicine and Genetics, Addenbrookes Hospital, Cambridge, UK
Biochem Biophys Res Commun 347:669-77. 2006....
- PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cellsGuizhu Hong
Translational Medicine and Technology, GlaxoSmithKline, ACCI, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2GG, UK
FASEB J 17:1966-8. 2003..This pathway may play a role in sodium retention caused by activation of PPARgamma in man...
- Monitoring the amyloid beta-peptide in vivo--caveat emptorPaul W Thompson
GlaxoSmithKline, R and D China, UK Hub, Cambridge, UK
Drug Discov Today 14:241-51. 2009..Additional candidate biofluid (tau and isoprostanes) and imaging (MRI, FDG-PET) measures may provide alternative supporting evidence of drug activity and subsequent clinical efficacy in patient populations...
- Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologiesPaul W Thompson
GlaxoSmithKline, R and D China, UK Hub, Addenbrookes Hospital, Cambridge, UK
J Neurochem 109:623-30. 2009....